236 related articles for article (PubMed ID: 23103095)
1. Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.
Zhang Q; Xia Z; Mitten MJ; Lasko LM; Klinghofer V; Bouska J; Johnson EF; Penning TD; Luo Y; Giranda VL; Shoemaker AR; Stewart KD; Djuric SW; Vasudevan A
Bioorg Med Chem Lett; 2012 Dec; 22(24):7615-22. PubMed ID: 23103095
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM
Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702
[TBL] [Abstract][Full Text] [Related]
3. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
Lu S; Sun SL; Liu HC; Chen YD; Yuan HL; Gao YP; Yang P; Lu T
Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481
[TBL] [Abstract][Full Text] [Related]
5. Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors.
Sun J; Lv PC; Guo FJ; Wang XY; Xiao-Han ; Zhang Y; Sheng GH; Qian SS; Zhu HL
Eur J Med Chem; 2014 Jun; 81():420-6. PubMed ID: 24859762
[TBL] [Abstract][Full Text] [Related]
6. Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.
Beria I; Ballinari D; Bertrand JA; Borghi D; Bossi RT; Brasca MG; Cappella P; Caruso M; Ceccarelli W; Ciavolella A; Cristiani C; Croci V; De Ponti A; Fachin G; Ferguson RD; Lansen J; Moll JK; Pesenti E; Posteri H; Perego R; Rocchetti M; Storici P; Volpi D; Valsasina B
J Med Chem; 2010 May; 53(9):3532-51. PubMed ID: 20397705
[TBL] [Abstract][Full Text] [Related]
7. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B
Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862
[TBL] [Abstract][Full Text] [Related]
8. Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1.
Richter S; Neundorf I; Loebner K; Gräber M; Berg T; Bergmann R; Steinbach J; Pietzsch J; Wuest F
Bioorg Med Chem Lett; 2011 Aug; 21(16):4686-9. PubMed ID: 21778054
[TBL] [Abstract][Full Text] [Related]
9. Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells.
Li P; Li Y; Ma X; Li L; Zeng S; Peng Y; Liang H; Zhang G
Eur J Med Chem; 2024 May; 271():116416. PubMed ID: 38657480
[TBL] [Abstract][Full Text] [Related]
10. 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors.
Beria I; Valsasina B; Brasca MG; Ceccarelli W; Colombo M; Cribioli S; Fachin G; Ferguson RD; Fiorentini F; Gianellini LM; Giorgini ML; Moll JK; Posteri H; Pezzetta D; Roletto F; Sola F; Tesei D; Caruso M
Bioorg Med Chem Lett; 2010 Nov; 20(22):6489-94. PubMed ID: 20932759
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
[TBL] [Abstract][Full Text] [Related]
13. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
Shan HM; Shi Y; Quan J
ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
[TBL] [Abstract][Full Text] [Related]
14. Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.
Rheault TR; Donaldson KH; Badiang-Alberti JG; Davis-Ward RG; Andrews CW; Bambal R; Jackson JR; Cheung M
Bioorg Med Chem Lett; 2010 Aug; 20(15):4587-92. PubMed ID: 20594842
[TBL] [Abstract][Full Text] [Related]
15. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
Uckun FM; Dibirdik I; Qazi S; Vassilev A; Ma H; Mao C; Benyumov A; Emami KH
Bioorg Med Chem; 2007 Jan; 15(2):800-14. PubMed ID: 17098432
[TBL] [Abstract][Full Text] [Related]
16. Imidazo[5,1-f][1,2,4]triazin-2-amines as novel inhibitors of polo-like kinase 1.
Cheung M; Kuntz KW; Pobanz M; Salovich JM; Wilson BJ; Andrews CW; Shewchuk LM; Epperly AH; Hassler DF; Leesnitzer MA; Smith JL; Smith GK; Lansing TJ; Mook RA
Bioorg Med Chem Lett; 2008 Dec; 18(23):6214-7. PubMed ID: 18929484
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
18. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
Lv X; Yang X; Zhan MM; Cao P; Zheng S; Peng R; Han J; Xie Z; Tu Z; Liao C
Eur J Med Chem; 2019 Dec; 184():111769. PubMed ID: 31629162
[TBL] [Abstract][Full Text] [Related]
20. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
Forsyth T; Kearney PC; Kim BG; Johnson HW; Aay N; Arcalas A; Brown DS; Chan V; Chen J; Du H; Epshteyn S; Galan AA; Huynh TP; Ibrahim MA; Kane B; Koltun ES; Mann G; Meyr LE; Lee MS; Lewis GL; Noguchi RT; Pack M; Ridgway BH; Shi X; Takeuchi CS; Zu P; Leahy JW; Nuss JM; Aoyama R; Engst S; Gendreau SB; Kassees R; Li J; Lin SH; Martini JF; Stout T; Tong P; Woolfrey J; Zhang W; Yu P
Bioorg Med Chem Lett; 2012 Dec; 22(24):7653-8. PubMed ID: 23127890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
